Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles

Cancer Gene Therapy volume 24, pages 233–243 (2017)Cite this article

Subjects

Abstract

Cancer is one of the leading cause of death in the world with the prevalence of >10 million mortalities annually. Current cancer treatments include surgical intervention, radiation, and taking chemotherapeutic drugs, which often kill the healthy cells and result in toxicity in patients. Therefore, researchers are looking for ways to be able to eliminate just cancerous cells. Intra-tumor heterogeneity of cancerous cells is the main obstacle on the way of an effective cancer treatment. However, better comprehension of molecular basis of tumor and the advent of new diagnostic technologies can help to improve the treatment of various cancers. Therefore, study of epigenetic changes, gene expression of cancerous cells and employing methods that enable us to correct or minimize these changes is critically important. In this paper, we will review the recent advanced strategies being used in the field of cancer research.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

References

  1. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW . Cancer genome landscapes. Science 2013; 339: 1546–1558.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Jones PA, Laird PW . Cancer-epigenetics comes of age. Nat Genet 1999; 21: 163–167.

    Article  CAS  PubMed  Google Scholar 

  3. Jones PA, Baylin SB . The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415–428.

    Article  CAS  PubMed  Google Scholar 

  4. Baylin SB, Ohm JE . Epigenetic gene silencing in cancer–a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107–116.

    Article  CAS  PubMed  Google Scholar 

  5. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108–1113.

    Article  CAS  PubMed  Google Scholar 

  6. Ryan BM, Robles AI, Harris CC . Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010; 10: 389–402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Zhang W, Dahlberg JE, Tam W . MicroRNAs in tumorigenesis: a primer. Am J Pathol 2007; 171: 728–738.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kasinski AL, Slack FJ . MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011; 11: 849–864.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Friedman JM, Liang G, Liu C-C, Wolff EM, Tsai YC, Ye W et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res 2009; 69: 2623–2629.

    Article  CAS  PubMed  Google Scholar 

  10. Fabbri M, Calin GA . Epigenetics and miRNAs in human cancer. Adv Genet 2010; 70: 87–99.

    Article  CAS  PubMed  Google Scholar 

  11. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006; 9: 435–443.

    Article  CAS  PubMed  Google Scholar 

  12. Kelly TK, De Carvalho DD, Jones PA . Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010; 28: 1069–1078.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Mattick JS, Amaral PP, Dinger ME, Mercer TR, Mehler MF . RNA regulation of epigenetic processes. Bioessays 2009; 31: 51–59.

    Article  CAS  PubMed  Google Scholar 

  14. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Morales DR et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci 2009; 106: 11667–11672.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Simon JA, Kingston RE . Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 2009; 10: 697–708.

    Article  CAS  PubMed  Google Scholar 

  16. Gutschner T, Diederichs S . The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 2012; 9: 703–719.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 2010; 142: 409–419.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Visone R, Croce CM . MiRNAs and cancer. Am J Pathol 2009; 174: 1131–1138.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257–2261.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25: 2537–2545.

    Article  CAS  PubMed  Google Scholar 

  21. Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006; 24: 4677–4684.

    Article  CAS  PubMed  Google Scholar 

  22. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425–436.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008; 26: 462–469.

    Article  CAS  PubMed  Google Scholar 

  24. Ma L, Teruya-Feldstein J, Weinberg RA . Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682–688.

    Article  CAS  PubMed  Google Scholar 

  25. McManus MT, MicroRNAs and Cancer. Seminars in Cancer Biology. Elsevier, 2003.

    Google Scholar 

  26. Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R et al. MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci USA 2006; 103: 5078–5083.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006; 130: 2113–2129.

    Article  CAS  PubMed  Google Scholar 

  28. Ørom UA, Kauppinen S, Lund AH . LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 2006; 372: 137–141.

    Article  PubMed  CAS  Google Scholar 

  29. Weiler J, Hunziker J, Hall J . Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Therapy 2006; 13: 496–502.

    Article  CAS  PubMed  Google Scholar 

  30. Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005; 438: 685–689.

    Article  PubMed  CAS  Google Scholar 

  31. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464: 1071–1076.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Yang Z, Zhou L, Wu L-M, Lai M-C, Xie H-Y, Zhang F et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol 2011; 18: 1243–1250.

    Article  PubMed  Google Scholar 

  33. Tong Y-K, Lo YD . Diagnostic developments involving cell-free (circulating) nucleic acids. Clin Chim Acta 2006; 363: 187–196.

    Article  CAS  PubMed  Google Scholar 

  34. De La Taille A . Progensa PCA3 test for prostate cancer detection. Exp Rev Mol Diagnos 2007; 7: 491–497.

    Article  CAS  Google Scholar 

  35. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev 2011; 25: 1915–1927.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Chan KA, Jiang P, Zheng YW, Liao GJ, Sun H, Wong J et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 2013; 59: 211–224.

    Article  CAS  PubMed  Google Scholar 

  37. Smaldone MC, Davies BJ . BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers. Curr Opin Mol Ther 2010; 12: 607–616.

    CAS  PubMed  Google Scholar 

  38. Guo F, Li Y, Liu Y, Wang J, Li Y, Li G . Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion. Acta Biochim Biophys Sin 2010; 42: 224–229.

    Article  CAS  PubMed  Google Scholar 

  39. Scherr M, Eder M . Gene silencing by small regulatory RNAs in mammalian cells. Cell Cycle 2007; 6: 444–449.

    Article  CAS  PubMed  Google Scholar 

  40. Bahramian MB, Zarbl H . GENE impedance: a natural process for control of gene expression and the origin of RNA interference. J Theor Biol 2005; 233: 301–314.

    Article  CAS  PubMed  Google Scholar 

  41. Holoch D, Moazed D . Small-RNA loading licenses Argonaute for assembly into a transcriptional silencing complex. Nat Struct Mol Biol 2015; 22: 328–335.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. De Paula D, Bentley MVL, Mahato RI . Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 2007; 13: 431–456.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. McManus MT, Sharp PA . Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002; 3: 737–747.

    Article  CAS  PubMed  Google Scholar 

  44. Shuey DJ, McCallus DE, Giordano T . RNAi: gene-silencing in therapeutic intervention. Drug Discov Today 2002; 7: 1040–1046.

    Article  CAS  PubMed  Google Scholar 

  45. Chiu Y-L, Rana TM . siRNA function in RNAi: a chemical modification analysis. RNA 2003; 9: 1034–1048.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Jebali A, Kalantar SM, Hekmatimoghaddam S, Saffarzadeh N, Sheikha MH, Ghasemi N . Surface modification of tri-calcium phosphate nanoparticles by DOPE and/or anti-E6 antibody to enhance uptake of antisense of E6 mRNA. Colloids Surf B: Biointerfaces 2015; 126: 297–302.

    Article  CAS  PubMed  Google Scholar 

  47. Gomez-Navarro J, Curiel D, Douglas J . Gene therapy for cancer. Eur J Cancer 1999; 35: 867–885.

    Article  CAS  PubMed  Google Scholar 

  48. Hanahan D, Weinberg RA . The hallmarks of cancer. Cell 2000; 100: 57–70.

    Article  CAS  PubMed  Google Scholar 

  49. Guo J, Fisher KA, Darcy R, Cryan JF, O’Driscoll C . Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. Mol Biosyst 2010; 6: 1143–1161.

    CAS  PubMed  Google Scholar 

  50. Li S, Huang L . Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Therapy 2006; 13: 1313–1319.

    Article  CAS  PubMed  Google Scholar 

  51. Sinn P, Sauter S, McCray P . Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors–design, biosafety, and production. Gene Therapy 2005; 12: 1089–1098.

    Article  CAS  PubMed  Google Scholar 

  52. El-Aneed A . An overview of current delivery systems in cancer gene therapy. J Controlled Release 2004; 94: 1–14.

    Article  CAS  Google Scholar 

  53. Henderson DR. Adenovirus vectors containing cell status-specific response elements and methods of use thereof. Google Patents. 2005.

  54. Borunda JA, Cordova EA. Recombinant adenoviral vectors and their utility in the treatment of various types of fibrosis: hepatic, renal, pulmonary, as well as hypertrophic scars. Google Patents. 2011.

  55. Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Annu Rev Biochem 2005. 74: 711–738.

    Article  CAS  PubMed  Google Scholar 

  56. Robbins PD, Ghivizzani SC . Viral vectors for gene therapy. Pharmacol Ther 1998; 80: 35–47.

    Article  CAS  PubMed  Google Scholar 

  57. Shen Y, Nemunaitis J . Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther 2006; 13: 975–992.

    Article  CAS  PubMed  Google Scholar 

  58. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG . Non-viral vectors for gene-based therapy. Nat Rev Genet 2014; 15: 541–555.

    Article  CAS  PubMed  Google Scholar 

  59. Ozpolat B, Sood AK, Lopez-Berestein G . Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev 2014; 66: 110–116.

    Article  CAS  PubMed  Google Scholar 

  60. Ibraheem D, Elaissari A, Fessi H . Gene therapy and DNA delivery systems. Int J Pharm 2014; 459: 70–83.

    Article  CAS  PubMed  Google Scholar 

  61. Kim B-K, Hwang G-B, Seu Y-B, Choi J-S, Jin KS, Doh K-O . DOTAP/DOPE ratio and cell type determine transfection efficiency with DOTAP-liposomes. Biochim Biophys Acta–Biomembr 2015; 1848: 1996–2001.

    Article  CAS  Google Scholar 

  62. Wu GY, Wu CH . Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J Biol Chem 1987; 262: 4429–4432.

    CAS  PubMed  Google Scholar 

  63. Duncan R . Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006; 6: 688–701.

    Article  CAS  PubMed  Google Scholar 

  64. Ferrari M . Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005; 5: 161–171.

    Article  CAS  PubMed  Google Scholar 

  65. Lavan DA, McGuire T, Langer R . Small-scale systems for in vivo drug delivery. Nat Biotechnol 2003; 21: 1184–1191.

    Article  CAS  PubMed  Google Scholar 

  66. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007; 2: 751–760.

    Article  CAS  PubMed  Google Scholar 

  67. Arap W, Pasqualini R, Ruoslahti E . Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377–380.

    Article  CAS  PubMed  Google Scholar 

  68. Schraa AJ, Kok RJ, Moorlag HE, Bos EJ, Proost JH, Meijer DK et al. Targeting of RGD‐modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution study. Int J Cancer 2002; 102: 469–475.

    Article  CAS  PubMed  Google Scholar 

  69. Shegokar R, Müller RH . Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm 2010; 399: 129–139.

    Article  CAS  PubMed  Google Scholar 

  70. Jain KK . Nanomedicine: application of nanobiotechnology in medical practice. Med Princ Pract 2008; 17: 89–101.

    Article  CAS  PubMed  Google Scholar 

  71. Lim SB, Banerjee A, Önyüksel H . Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release 2012; 163: 34–45.

    Article  CAS  PubMed  Google Scholar 

  72. Cho K, Wang X, Nie S, Shin DM . Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008; 14: 1310–1316.

    Article  CAS  PubMed  Google Scholar 

  73. Di Costanzo F, Gasperoni S, Rotella V, Di Costanzo F . Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer. Onco Targets Ther 2009; 2: 179–188.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Tangney M . Gene therapy for cancer: dairy bacteria as delivery vectors. Discov Med 2010; 10: 195–200.

    PubMed  Google Scholar 

  75. Cabral H, Kataoka K . Progress of drug-loaded polymeric micelles into clinical studies. J Control Release 2014; 190: 465–476.

    Article  CAS  PubMed  Google Scholar 

  76. Yang J, Zhang Q, Chang H, Cheng Y . Surface-engineered dendrimers in gene delivery. Chem Rev 2015; 115: 5274–5300.

    Article  CAS  PubMed  Google Scholar 

  77. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN . Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 1997; 15: 647–652.

    Article  CAS  PubMed  Google Scholar 

  78. Wang R, Billone PS, Mullett WM . Nanomedicine in action: an overview of cancer nanomedicine on the market and in clinical trials. J Nanomater 2013; 2013: 1.

    Google Scholar 

  79. Çağdaş M, Sezer AD, Bucak S . Liposomes as potential drug carrier systems for drug delivery. Appl Nanotechnol Drug Deliv 2014: 1–100.

  80. Bumcrot D, Manoharan M, Koteliansky V, Sah DW . RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006; 2: 711–719.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Singhania R, Khairuddin N, Clarke D, McMillan NA . RNA interference for the treatment of papillomavirus disease. Open Virol J 2012; 6: 204–215.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Zamboni WC . Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 2005; 11: 8230–8234.

    Article  CAS  PubMed  Google Scholar 

  83. Zaimy M, Jebali A, Bazrafshan B, Mehrtashfar S, Shabani S, Tavakoli A et al. Coinhibition of overexpressed genes in acute myeloid leukemia subtype M2 by gold nanoparticles functionalized with five antisense oligonucleotides and one anti-CD33 (+)/CD34 (+) aptamer. Cancer Gene Therapy 2016; 23: 315–320.

    Article  CAS  PubMed  Google Scholar 

  84. Boddy AV, Plummer ER, Todd R, Sludden J, Griffin M, Robson L et al. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin Cancer Res 2005; 11: 7834–7840.

    Article  CAS  PubMed  Google Scholar 

  85. Sutton D, Nasongkla N, Blanco E, Gao J . Functionalized micellar systems for cancer targeted drug delivery. Pharm Res 2007; 24: 1029–1046.

    Article  CAS  PubMed  Google Scholar 

  86. Rahman AM, Yusuf SW, Ewer MS . Anthracycline induced cardiotoxicity and cardiac-sparing effect of liposomal formulation. Int J Nanomed 2007; 2: 567.

    CAS  Google Scholar 

  87. Safra T . Cardiac safety of liposomal anthracyclines. Oncologist 2003; 8 (Suppl 2): 17–24.

    Article  CAS  PubMed  Google Scholar 

  88. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13: 1777–1785.

    Article  CAS  PubMed  Google Scholar 

  89. Song CW . Effect of local hyperthermia on blood flow and microenvironment: a review. Cancer Res 1984; 44 (Suppl 10): 4721s–4730ss.

    CAS  PubMed  Google Scholar 

  90. Manzoor AA, Lindner LH, Landon CD, Park J-Y, Simnick AJ, Dreher MR et al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res 2012; 72: 5566–5575.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Zagar TM, Vujaskovic Z, Formenti S, Rugo H, Muggia F, O’Connor B et al. Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. Int J Hyperth 2014; 30: 285–294.

    Article  CAS  Google Scholar 

  92. Hirsch LR, Stafford R, Bankson J, Sershen S, Rivera B, Price R et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci 2003; 100: 13549–13554.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Huang X, Jain PK, El-Sayed IH, El-Sayed MA . Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers Med Sci 2008; 23: 217–228.

    Article  PubMed  Google Scholar 

  94. Melancon MP, Zhou M, Li C . Cancer theranostics with near-infrared light-activatable multimodal nanoparticles. Accounts of Chem Res 2011; 44: 947–956.

    Article  CAS  Google Scholar 

  95. Von Maltzahn G, Park J-H, Lin KY, Singh N, Schwöppe C, Mesters R et al. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater 2011; 10: 545–552.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Lovell JF, Jin CS, Huynh E, Jin H, Kim C, Rubinstein JL et al. Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents. Nat Mater 2011; 10: 324–332.

    Article  CAS  PubMed  Google Scholar 

  97. Yavuz MS, Cheng Y, Chen J, Cobley CM, Zhang Q, Rycenga M et al. Gold nanocages covered by smart polymers for controlled release with near-infrared light. Nat Mater 2009; 8: 935–939.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Tong R, Hemmati HD, Langer R, Kohane DS . Photoswitchable nanoparticles for triggered tissue penetration and drug delivery. J Am Chem Soc 2012; 134: 8848–8855.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Tong R, Chiang HH, Kohane DS . Photoswitchable nanoparticles for in vivo cancer chemotherapy. Proc Natl Acad Sci 2013; 110: 19048–19053.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Wang LV . Multiscale photoacoustic microscopy and computed tomography. Nat Photon 2009; 3: 503–509.

    Article  CAS  Google Scholar 

  101. Jain RK . Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987–989.

    Article  CAS  PubMed  Google Scholar 

  102. Chauhan VP, Stylianopoulos T, Martin JD, Popović Z, Chen O, Kamoun WS et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 2012; 7: 383–388.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Jayson GC, Kerbel R, Ellis LM, Harris AL . Antiangiogenic therapy in oncology: current status and future directions. Lancet 2016; 388: 518–529.

    Article  CAS  PubMed  Google Scholar 

  104. Mellman I, Coukos G, Dranoff G . Cancer immunotherapy comes of age. Nature 2011; 480: 480–489.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF . Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008; 38: 1404–1413.

    Article  CAS  PubMed  Google Scholar 

  106. Reddy ST, van der Vlies AJ, Simeoni E, Angeli V, Randolph GJ, O'Neil CP et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007; 25: 1159–1164.

    Article  CAS  PubMed  Google Scholar 

  107. Cho N-H, Cheong T-C, Min JH, Wu JH, Lee SJ, Kim D et al. A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy. Nat Nanotechnol 2011; 6: 675–682.

    Article  CAS  PubMed  Google Scholar 

  108. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME . Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8: 299–308.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Stephan MT, Moon JJ, Um SH, Bershteyn A, Irvine DJ . Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med 2010; 16: 1035–1041.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Cheetham S, Gruhl F, Mattick J, Dinger M . Long noncoding RNAs and the genetics of cancer. Br J Cancer 2013; 108: 2419–2425.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Davidson BL, McCray PB . Current prospects for RNA interference-based therapies. Nat Rev Genet 2011; 12: 329–340.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Morier DS . Human Monkeypox in the Democratic Republic of Congo: presentation. Prediction and Animal Exposures Associated with Rash Severity 2014.

Download references

Author information

Authors and Affiliations

  1. Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    M A Zaimy, N Saffarzadeh, P Izadi & J Tavakkoly-Bazzaz

  2. Center of Excellence for Biodiversity, Faculty of Natural Science, University of Tabriz, Tabriz, Iran

    A Mohammadi

  3. Department of Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    H Pourghadamyari

  4. Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

    A Sarli

  5. Department of Developmental Cell Biology, School of Biological Sciences, Azad University, Tehran North Branch, Tehran, Iran

    L K Moghaddam & S R Paschepari

  6. Department of Medical Parasitology, Zabol University of Medical Sciences, Zabol, Iran

    H Azizi

  7. Department of Medical Genetics and immunology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran

    S Torkamandi

Authors
  1. M A Zaimy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Saffarzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Mohammadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Pourghadamyari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Izadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Sarli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L K Moghaddam
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S R Paschepari
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H Azizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S Torkamandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J Tavakkoly-Bazzaz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Tavakkoly-Bazzaz.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zaimy, M., Saffarzadeh, N., Mohammadi, A. et al. New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles. Cancer Gene Ther 24, 233–243 (2017). https://doi.org/10.1038/cgt.2017.16

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2017.16

This article is cited by

Search

Advanced search

Quick links